Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Growth Hormone Secretion

CJC-1295 + Ipamorelin

Mod GRF(1-29) + Ipamorelin; CJC no-DAC + Ipa; GHRH+GHRP blend

GHRH analog + selective GHRP blend (GH-secretagogue stack)

This CJC-1295 + Ipamorelin entry draws on 3 cited sources published 1998 to 2006. The evidence available is graded Anecdotal + Animal Studies on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .

At a glance

Class
GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class
Growth Hormone Secretion
Structure
Co-formulated vial: ~2 mg CJC-1295 no-DAC (29-aa GHRH analog) + ~2 mg Ipamorelin (pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH2)
Route
SC injection
Half-life
CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Evidence tier
Anecdotal + Animal Studies
Availability
Compounding Restricted
Research depth
5 indexed citations (PubMed 0 · CT 0 · EPMC 5) →

Mechanism of action

Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).

Reported areas of research

Layered pituitary GH release; improved sleep architecture; recovery and lean body composition support; lower cortisol/prolactin signal than GHRH + GHRP-6 alternatives

Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.

Dosage protocols reported in literature

100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off

Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.

Known concerns and limitations

Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Compared with

CJC-1295 + Ipamorelin has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.

Frequently asked questions

What dosing is reported for CJC-1295 + Ipamorelin in research literature?

Published peptide research reports the following dosing approach for CJC-1295 + Ipamorelin: 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off. This is a research reference, not a clinical recommendation.

How is CJC-1295 + Ipamorelin administered in research?

CJC-1295 + Ipamorelin is administered via the following routes in published studies: SC injection.

What is the reported half-life of CJC-1295 + Ipamorelin?

The reported half-life of CJC-1295 + Ipamorelin is CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs.

Is CJC-1295 + Ipamorelin FDA-approved?

No. CJC-1295 + Ipamorelin is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.

What level of evidence supports CJC-1295 + Ipamorelin?

The current evidence base for CJC-1295 + Ipamorelin is best characterised as: Anecdotal + Animal Studies. See the methodology page for the full evidence-tier rubric.

What side effects are reported for CJC-1295 + Ipamorelin?

Known concerns reported in the literature for CJC-1295 + Ipamorelin include: Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication. Always consult a qualified clinician before any human use.

Is there anyone who should not use CJC-1295 + Ipamorelin?

No formal contraindications are established for CJC-1295 + Ipamorelin, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication. Always consult a qualified clinician before any human use.

How does CJC-1295 + Ipamorelin work?

The mechanism of action reported for CJC-1295 + Ipamorelin in the literature: Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm)..

What is CJC-1295 + Ipamorelin studied for?

CJC-1295 + Ipamorelin has been studied in the published literature for: Layered pituitary GH release; improved sleep architecture; recovery and lean body composition support; lower cortisol/prolactin signal than GHRH + GHRP-6 alternatives. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.

What is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is classified as: GHRH analog + selective GHRP blend (GH-secretagogue stack). Also known as: Mod GRF(1-29) + Ipamorelin; CJC no-DAC + Ipa; GHRH+GHRP blend.

Drug class

Research focus area

All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.

Primary sources

  1. Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab 2006. PMID 16352683
  2. Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
  3. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006. PMID 18046911

Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.

Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.

Loading interactive view…